# A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI9929 After Single Administration in Healthy Male Japanese Subjects

> **NCT01913028** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 64 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** MEDI9929
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01913028
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2014-01
- **Final completion:** 2014-01
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2014-02-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01913028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01913028, "A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of MEDI9929 After Single Administration in Healthy Male Japanese Subjects". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT01913028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*